Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Theo Young, BS
Student
University of Mississippi School of Pharmacy
Jackson, MS
Student, University of Mississippi School of Pharmacy, Jackson, and was a summer intern at the University of Tennessee College of Pharmacy, Memphis, at the time of this study
Authored Items
Trends in Medicare Part D Medication Therapy Management Eligibility Criteria
Junling Wang, PhD
,
Ya-Chen Tina Shih, PhD
,
Yolanda Qin
,
Theo Young, BS
,
Zachary Thomas, MS, MBA
,
Christina A. Spivey, PhD
,
David K. Solomon, BSc, PharmD
,
Marie Chisholm-Burns, PharmD, MPH, MBA, FCCP, FASHP
,
J. Warren Salmon, PhD
,
J. Warren Salmon, PhD
July/August 2015 Vol 8 No 5
in
Practice Management
Last modified: August 31, 2015